Fetal growth restriction and methylation of growth-related genes in the placenta

Epigenomics

Volumn 8, Issue 1, 2016, Pages 33-42

  Xiao, Xirong ^a   Zhao, Yan ^a   Jin, Rong ^b   Chen, Jiao ^a   Wang, Xiu ^a   Baccarelli, Andrea ^c   Zhang, Yunhui ^a  

^a FUDAN UNIVERSITY   (China)

^b School of Medicine   (China)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

birth weight; case control study; DNA methylation; fetal growth restriction; placenta

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; BISULFITE; WNT2 PROTEIN; AHRR PROTEIN, HUMAN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; HSD11B2 PROTEIN, HUMAN; IGF2 PROTEIN, HUMAN; REPRESSOR PROTEIN; SOMATOMEDIN B; WNT2 PROTEIN, HUMAN;

ADULT; AHRR GENE; BIRTH WEIGHT; BODY MASS; CONTROLLED STUDY; DNA METHYLATION; FEMALE; FETUS GROWTH; GENE; HUMAN; IGF2 GENE; IL6 GENE; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; MALE; NEWBORN; NR3C1 GENE; PLACENTA; PREGNANCY OUTCOME; PRIORITY JOURNAL; PYROSEQUENCING; REVIEW; CASE CONTROL STUDY; DNA SEQUENCE; EMBRYOLOGY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PREGNANCY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIRTH WEIGHT; CASE-CONTROL STUDIES; DNA METHYLATION; FEMALE; FETAL GROWTH RETARDATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR II; MALE; PLACENTA; PREGNANCY; REPRESSOR PROTEINS; SEQUENCE ANALYSIS, DNA; WNT2 PROTEIN;

EID: 84954495805     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.15.101     Document Type: Review

References (34)

1. Longo S, Bollani L, Decembrino L, Di Comite A, Angelini M, Stronati M. Short-term and long-term sequelae in intrauterine growth retardation (IUGR). J. Matern. Fetal. Neonatal. Med. 26(3), 222-225 (2013).
2. Brodsky D, Christou H. Current concepts in intrauterine growth restriction. J. Intensive. Care Med. 19(6), 307-319 (2004).
3. Ross MG, Beall MH. Adult sequelae of intrauterine growth restriction. Semin. Perinatol. 32(3), 213-218 (2008).
4. Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N. Engl. J. Med. 359(1), 61-73 (2008).
5. Gillman MW. Developmental origins of health and disease. N. Engl. J. Med. 353(17), 1848-1850 (2005).
6. Robins JC, Marsit CJ, Padbury JF, Sharma SS. Endocrine disruptors, environmental oxygen, epigenetics and pregnancy. Front. Biosci. 3, 690-700 (2011).
7. Nelissen EC, Van Montfoort AP, Dumoulin JC, Evers JL. Epigenetics and the placenta. Hum. Reprod. Update 17(3), 397-417 (2011).
8. Tycko B. Imprinted genes in placental growth and obstetric disorders. Cytogenet. Genome. Res. 113(1-4), 271-278 (2006).
9. Hemberger M. Epigenetic landscape required for placental development. Cell. Mol. Life. Sci. 64(18), 2422-2436 (2007).
10. Du M, Zhou W, Beatty LG, Weksberg R, Sadowski PD. The KCNQ1OT1 promoter, a key regulator of genomic imprinting in human chromosome 11p15.5. Genomics 84(2), 288-300 (2004).
11. St-Pierre J, Hivert MF, Perron P et al. IGF2 DNA methylation is a modulator of newborn's fetal growth and development. Epigenetics 7(10), 1125-113 (2012).
12. Cordeiro A, Neto AP, Carvalho F, Ramalho C, Doria S. Relevance of genomic imprinting in intrauterine human growth expression of CDKN1C, H19, IGF2, KCNQ1 and PHLDA2 imprinted genes. J. Assist. Reprod. Genet. 31(10),1361-1368 (2014).
13. Bourque DK, Avila L, Penaherrera M, Von Dadelszen P, Robinson WP. Decreased placental methylation at the H19/IGF2 imprinting control region is associated with normotensive intrauterine growth restriction but not preeclampsia. Placenta 31(3), 197-202 (2010).
14. Stewart PM, Murry BA, Mason JI. Type 2 betahydroxysteroid dehydrogenase in human fetal tissues. J. Clin. Endocrinol. Metab. 78(6), 1529-1532 (1994).
15. Marsit CJ, Maccani MA, Padbury JF, Lester BM. Placental 11-beta hydroxysteroid dehydrogenase methylation is associated with newborn growth and a measure of neurobehavioral outcome. PLoS ONE 7(3), e33794 (2012).
16. Zhao Y, Gong X, Chen L et al. Site-specific methylation of placental HSD11B2 gene promoter is related to intrauterine growth restriction. Eur. J. Hum. Genet. 22(6), 734-740 (2014).
17. Ferreira JC, Choufani S, Grafodatskaya D et al. WNT2 promoter methylation in human placenta is associated with low birth weight percentile in the neonate. Epigenetics 6(4), 440-449 (2011).
18. Filiberto AC, Maccani MA, Koestler D et al. Birthweight is associated with DNA promoter methylation of the glucocorticoid receptor in human placenta. Epigenetics 6(5), 566-572 (2011).
19. Zhao Y, Shi HJ, Xie CM, Chen J, Laue H, Zhang YH. Prenatal phthalate exposure, infant growth, and global DNA methylation of human placenta. Environ. Mol. Mutagen. 56(3), 286-292 (2015).
20. Valero De Bernabe J, Soriano T, Albaladejo R et al. Risk factors for low birth weight: a review. Eur. J. Obstet. Gynecol. Reprod. Biol. 116(1), 3-15 (2004).
21. Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the use of head, body, and femur measurements-a prospective study. Am. J. Obstet. Gynecol. 151(3), 333-337 (1985).
22. Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet. Gynecol. 87(2), 163-168 (1996).
23. Chang TC, Robson SC, Spencer JA, Gallivan S. Identification of fetal growth retardation: comparison of Doppler waveform indices and serial ultrasound measurements of abdominal circumference and fetal weight. Obstet. Gynecol. 82(2), 230-236 (1993).
24. Mcternan CL, Draper N, Nicholson H et al. Reduced placental 11 beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible me mechanisms. J. Clin. Endocrinol. Metab. 86(10), 4979-4983 (2001).
25. Nishizawa H, Ota S, Suzuki M et al. Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction. Reprod. Biol. Endocrinol. 9, 107 (2011).
26. Street ME, Seghini P, Fieni S et al. Changes in interleukin-6 and IGF system and their relationships in placenta and cord blood in newborns with fetal growth restriction compared with controls. Eur. J. Endocrinol. 155(4), 567-574 (2006).
27. Maccani MA, Marsit CJ. Epigenetics in the placenta. Am. J. Reprod. Immunol. 62(2), 78-89 (2009).
28. Li F, Chong ZZ, Maiese K. Winding through the WNT pathway during cellular development and demise. Histol. Histopathol. 21(1), 103-124 (2006).
29. Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CR. Glucocorticoid exposure in utero: new model for adult hypertension. Lancet 341(8841), 339-341 (1993).
30. Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 202 (4366), 436-438 (1978).
31. Oakley RH, Cidlowski JA. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J. Allergy. Clin. Immunol. 132(5), 1033-1044 (2013).
32. Zudaire E, Cuesta N, Murty V et al. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J. Clin. Invest. 118(2), 640-650 (2008).
33. Opitz CA, Litzenburger UM, Sahm F et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478(7368), 197-203 (2011).
34. Joubert BR, Haberg SE, Nilsen RM et al. 450K epigenomewide scan identifies differential DNA methylation in newborns related to maternal smoking during pregnancy. Environ. Health. Perspect. 120(10), 1425-1431 (2012).